Lung Cancer Dispatch
Follow
Find tag "MEK"
3.5K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

New Targeted Drugs May Offer Treatment for KRAS-Mutant Lung Cancer

New Targeted Drugs May Offer Treatment for KRAS-Mutant Lung Cancer | Lung Cancer Dispatch | Scoop.it

Abnormalities in the KRAS gene are the most common mutations in lung cancer, especially in lung adenocarcinoma, a type of non-small cell lung cancer (NSCLC). However, no effective targeted therapy directed at KRAS has been found. Instead, researchers have begun to focus on blocking molecules 'downstream' in the chain of chemical reactions through which KRAS affects the cell. Two such molecules are TBK1 and MEK. A recent study found that the drug CYT387 blocks TBK1. CYT387 reduced tumor growth in mice with KRAS-mutant lung adenocarcinoma. Also in mice, CYT387 and the MEK inhibitor AZD6244, given together, shrank aggressive lung tumors with mutations in both the KRAS and the TP53 gene. Researchers now hope to investigate the two drugs in people.

Cancer Commons's insight:

ASCO Post  |  Jan 29, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Combined Gene Inhibition May Offer Treatment Strategy for Certain Lung Cancers

KRAS is a gene that is mutated in many cancers, including around 30% of lung cancers, but no targeted therapies for KRAS-mutant cancers exist yet. Researchers found that blocking two genes that are part of the KRAS signaling pathway, MEK and BCL-XL, using the targeted inhibitors selumetinib (for MEK) and navitoclax (for BCL-XL) shrank tumors in mouse lung cancer models and human tumor samples. While MEK inhibition alone is not effective in KRAS-mutant lung cancer, combining MEK and BCL-XL inhibitors may offer a promising therapeutic approach.

 

Primary source: http://www.sciencedirect.com/science/article/pii/S1535610812004874

Cancer Commons's insight:

Cancer Cell | Dec 13, 2012

more...
No comment yet.